title: Asymptomatic oral carriage of Candida albicans in patients with HIV infection.
abstract: OBJECTIVE
  To assess the relationship of asymptomatic carriage of Candida albicans and clinically apparent thrush in patients with HIV infection.
  
  
  METHODS
  Prospective, longitudinal, controlled study.
  
  
  METHODS
  The HIV clinic at St. Michael's Hospital, University of Toronto.
  
  
  METHODS
  One hundred and twenty-seven patients with HIV-infection were divided into 3 groups according to the CD4+ lymphocyte count, and 37 healthy volunteers served as controls.
  
  
  METHODS
  Determination of blood type, baseline CD4+ lymphocyte count in patients with HIV infection, and immunophenotyping. Samples of saliva (2 mL) were obtained from each patient and control.
  
  
  METHODS
  Carrier status, clinical presence of thrush, the association between carriage of C. albicans and blood type, secretor status and history of oral infection.
  
  
  RESULTS
  In patients with HIV infection and C albicans colonization no correlation was found with blood type or secretor status of blood group antigen in the saliva. The frequency of oral carriage of yeast was greater in patients infected with HIV than in controls, but the difference was not significant for asymptomatic subjects with a CD4+ lymphocyte count greater than 500/microL. Persistent carriage of yeast and development of clinical thrush were associated with lower CD4+ counts. Clinical thrush developed only in patients with persistent asymptomatic carriage of C. albicans and CD4+ counts less than 500/microL.
  
  
  CONCLUSIONS
  The greater risk of oral colonization with C. albicans in patients with HIV infection partly explains the high prevalence of thrush found in this group.
authors.affiliation: St. Michael's Hospital, University of Toronto, Ont.
authors.forename: I W
authors.initials: IW
authors.lastname: Fong
authors.forename: M
authors.initials: M
authors.lastname: Laurel
authors.forename: A
authors.initials: A
authors.lastname: Burford-Mason
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001788:Blood Grouping and Crossmatching; D002180:Candidiasis, Oral / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D002353:Carrier State / Q000175:diagnosis / Q000453:epidemiology*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006304:Health Status; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents